EGFR and neoplasm: Indeed, poziotinib is also a potent inhibitor of wild-type EGFR [52], raising concerns that poziotinib may show a narrow therapeutic window, linked to insufficient therapeutic dosing due to toxicity and therefore contributing to short-term tumour responses.